ISL
14.10.2019 12:51:06 CEST | Business Wire | Press release
The second and final day of the International Swimming League’s first tour of Europe proved to be the most exciting of the young season thus far, as a sold out crowd at the Piscina Felipe Scandone in Naples, Italy, were treated to a pair of tight club battles that came down to the final event.
The passion of the European fans was very evident to those competing, giving them a boost late in the match.
“It's really cool how great this has been unfolding,” said Cali Condor’s Caeleb Dressel , who was named MVP with a match-high 57.5 points. “Again this is my first meet, but everyone loved Indy. And this is, I think, even a step up from that because it's in Europe this time. I think the fans are a little bit crazier, a little bit better, a little bit more into it.”
"This is a whole other level of things. I mean, the crowd for one, but the lights, the DJ, the walkout, it makes it seem like an event. Not just something that you get to watch, but you feel like you're a part of it.”
“The energy on deck, I can still feel it right now as I'm sitting here,” said DC Trident captain Cody Miller in a post-match media scrum. “It was awesome, it was a lot of fun, and I think that there's just more greatness to come. It was so, so fun.”
Another thing that stood out to Miller was the noise, which was exaggerated due to the way the building was constructed.
"I think probably cause the pool is mostly made of concrete...the noise! I have not been to many facilities where the noise is that awesome, it makes it fun. It makes it fun for us, it makes it fun for people that are watching,” said Miller enthusiastically.
“I think that makes a big difference with the energy levels,” said Energy Standard male captain Chad Le Clos on how the crowd impacted the match. “Doing back-to-back races - 50 fly, 200 fly, 100 freestyle - getting back up (on the blocks) was very special, and a big thank you to the crowd. Altogether it was a great show.”
DC Trident coach Cyndi Gallagher had a similar perspective as the athletes, really enjoying the vibe that the match produced.
“I think this is super fun, exciting,” Gallagher said in an interview during one of the breaks. “I love the crowd, I love that they're getting the crowd into it, the music, the DJ, our energy is great. We are all in.”
Sarah Sjostrom , a Swede who is one of the sport’s biggest stars in Europe, always loves swimming in front of an Italian crowd.
"They love the Italian swimmers, but they do love the other swimmers as well,” said the 2016 Olympic gold medalist. “The other swimming stars, even if you're from Sweden. I always love racing in Italy. So it's a lot of fun to have very good supporters here in the stands.”
The match was tightly contested for first place between Energy Standard, who won last weekend in Indianapolis, and the Cali Condors, who received a significant boost with Dressel making his debut.
Dressel went out and won the final event, the men’s skins, which are worth triple the points. However, his Energy Standard counterparts Florent Manaudou and Ben Proud placed second and third to secure another win for their club.
"It hurts. I mean, I'd much rather have a team title than MVP, 100 percent of the time,” said Dressel, who won a total of four individual events over the two days. “It definitely stings, but it's cool, there's already started (to be) rivalries (developing) and stuff. Of course, friendly rivalries. I respect everyone on that team, but I would've liked to win the meet. And it was so close which is what makes it hurt a little bit more.”
The 23-year-old is confident the Condors will continue to improve and have a good chance of winning it all at the league grand final in Vegas in December.
“I could've been better throughout the meet and scored more points, we all could've been, everyone across the board. We're on a good progression for now, from Indy to here, so we'll find some more room to be better, and then hopefully by Vegas we'll have it figured out.”
Miller’s Trident club was locked in a close race with the hometown Aqua Centurions, going back and forth throughout the match in the race for third.
“We have two teams, my team (DC Trident) and the Aqua Centurions, vying for just a few points here and there. It feels like it's an NBA game. It feels like a basketball game,” he said. “We were a ways behind the two front-running teams, but were still in a tight race with another team, so, it's exciting.”
“There's a rivalry. It's a good rivalry, It's been fun.”
About the ISL: The International Swimming League is a global professional swimming competition launching in 2019 with teams in both Europe (Italy-based Aqua Centurions, France-based Energy Standard, Hungary-based Iron, and London Roar) and the United States (Cali Condors, DC Trident, LA Current, NY Breakers). The inaugural season will include matches in Indianapolis IN, Naples ITA, Lewisville TX, Budapest HUN, College Park MD, London GBR, and the championship finale at the 12,000-seat Mandalay Bay Events Center in Las Vegas, NV. The ISL aims to create groundbreaking projects, in both form and content, exploring the full potential of competitive swimming while securing sustainable commercial growth in the sport.
Key Dates:
5-6 October 2019 – IU Natatorium, Indianapolis, USA
12-13 October 2019 – Aquatic Swimming Complex, Naples, Italy
19-20 October 2019 – The LISD Westside Aquatic Center, Lewisville, Texas, USA
26-27 October 2019 – Duna Area, Budapest, Hungary
16-17 November 2019 – Natatorium at the Eppley Recreation Center, Maryland, USA
23-24 November 2019 – London Aquatic Centre, Great Britain
20-21 December 2019 – Mandalay Bay Resort and Casino, Las Vegas, USA
ISL SOCIAL:
Keep up with all the latest ISL news by following @iswimleague on Instagram and Twitter and @internationalswimmingleague on Facebook.
Visit https://isl.global
For latest images, video and stories go to
http://apmultimedianewsroom.com/multimedia-newsroom/partners/international-swimming-league
View source version on businesswire.com: https://www.businesswire.com/news/home/20191014005313/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
